Eric D. Brown, PhD
Director, Biomedical Discovery and Commercialization
- Microbiological Biochemistry
- Antimicrobial Research
Dr. Brown’s research interests are in studying complex and poorly understood aspects of biology in bacteria using molecular genetic and biochemical approaches. Brown lab researchers are currently studying cell wall and ribosome biogenesis, both daunting cellular processes of remarkable complexity. Further, Dr. Brown oversees an ambitious effort in chemical genomics aimed at mapping and understanding the interaction of drug-like small molecules with bacterial cell systems.
In the past forty years, only two new classes of antibiotics have reached the clinic for treatment of bacterial infections. During this time we have seen an alarming increase in reports of “superbugs” that are resistant to all existing antibiotics. Indeed, multi-drug resistance amoung bacterial pathogens is largely due to the limited number of drugs that eradicate bacteria with a narrow range of measures. Recognizing the need for new therapies with novel mechanisms of action, we have mounted research projects in areas of bacterial physiology of emerging importance in antibacterial drug discovery.